Frontiers in Oncology (Aug 2022)

Radiation Oncology: Future Vision for Quality Assurance and Data Management in Clinical Trials and Translational Science

  • Linda Ding,
  • Carla Bradford,
  • I-Lin Kuo,
  • Yankhua Fan,
  • Kenneth Ulin,
  • Abdulnasser Khalifeh,
  • Suhong Yu,
  • Fenghong Liu,
  • Jonathan Saleeby,
  • Harry Bushe,
  • Koren Smith,
  • Camelia Bianciu,
  • Salvatore LaRosa,
  • Fred Prior,
  • Joel Saltz,
  • Ashish Sharma,
  • Mark Smyczynski,
  • Maryann Bishop-Jodoin,
  • Fran Laurie,
  • Matthew Iandoli,
  • Janaki Moni,
  • M. Giulia Cicchetti,
  • Thomas J. FitzGerald

DOI
https://doi.org/10.3389/fonc.2022.931294
Journal volume & issue
Vol. 12

Abstract

Read online

The future of radiation oncology is exceptionally strong as we are increasingly involved in nearly all oncology disease sites due to extraordinary advances in radiation oncology treatment management platforms and improvements in treatment execution. Due to our technology and consistent accuracy, compressed radiation oncology treatment strategies are becoming more commonplace secondary to our ability to successfully treat tumor targets with increased normal tissue avoidance. In many disease sites including the central nervous system, pulmonary parenchyma, liver, and other areas, our service is redefining the standards of care. Targeting of disease has improved due to advances in tumor imaging and application of integrated imaging datasets into sophisticated planning systems which can optimize volume driven plans created by talented personnel. Treatment times have significantly decreased due to volume driven arc therapy and positioning is secured by real time imaging and optical tracking. Normal tissue exclusion has permitted compressed treatment schedules making treatment more convenient for the patient. These changes require additional study to further optimize care. Because data exchange worldwide have evolved through digital platforms and prisms, images and radiation datasets worldwide can be shared/reviewed on a same day basis using established de-identification and anonymization methods. Data storage post-trial completion can co-exist with digital pathomic and radiomic information in a single database coupled with patient specific outcome information and serve to move our translational science forward with nimble query elements and artificial intelligence to ask better questions of the data we collect and collate. This will be important moving forward to validate our process improvements at an enterprise level and support our science. We have to be thorough and complete in our data acquisition processes, however if we remain disciplined in our data management plan, our field can grow further and become more successful generating new standards of care from validated datasets.

Keywords